GI Dynamics has a fresh set of positive clinical results from three studies of its EndoBarrier Gastrointestinal Liner, a device used to treat type 2 diabetes, weight loss and other metabolic factors. And results from one study showed that EndoBarrier had an impact on hormonal activity in patients with the device.
GI describes the EndoBarrier is a non-surgical, removable, physical barrier (pictured here) that enables food to bypass portions of the intestine. It has a similar effect as gastric bypass with fewer associated risks. The device can "reset" the body's metabolic functions to a more normalized state.
In a 24-week trial with 17 people, researchers found that the device improved insulin sensitivity, promoted weight loss and helped patients reduce their use of anti-diabetic medications. "These data reveal that EndoBarrier treatment affects key hormones involved in insulin sensitivity and satiety, which is likely the cause for the rapid improvement seen in type 2 diabetes," said study leader Professor Jan Willem Greve. "This supports the belief that the EndoBarrier works by affecting hormone activation and that the device is a promising tool for the treatment of type 2 diabetes in obese individuals."
The company believes the trial results support EndoBarrier as primary therapy for the treatment of type 2 diabetes and obesity in patients with a body mass index (BMI) greater than 30 who haven't succeeded with lifestyle changes and drugs alone.
- take a look at the release